Such analyses might have sufficient power to assess effects of SGLT2 inhibitors in individuals with slowly progressive chronic kidney disease in whom data are limited (eg, patients with chronic kidney disease with low levels of albuminuria). The gene discussed is SLC5A2; the disease is chronic kidney disease.